IPP Bureau
Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections
By IPP Bureau - October 01, 2025
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
GSK names Luke Miels as next CEO
By IPP Bureau - September 30, 2025
Miels will formally assume the role on January 1, 2026
BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu
By IPP Bureau - September 30, 2025
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare
By IPP Bureau - September 30, 2025
The Hub & Spoke model is designed to extend advanced medical care to a wider community
Brenntag showcases innovations in beauty and personal care at Indonesia Cosmetic Ingredients 2025
By IPP Bureau - September 30, 2025
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients
By IPP Bureau - September 30, 2025
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia
By IPP Bureau - September 30, 2025
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra
By IPP Bureau - September 30, 2025
The platform is being introduced to expand access to treatments for people living with chronic conditions
Revvity launches AI-powered software to transform preclinical imaging analysis
By IPP Bureau - September 30, 2025
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Experts highlight critical link between mental well-being and cardiovascular health
By IPP Bureau - September 29, 2025
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
By IPP Bureau - September 29, 2025
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Moderna’s mNEXSPIKE generates strong immune response against LP.8.1 variant in humans
By IPP Bureau - September 29, 2025
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025
By IPP Bureau - September 29, 2025
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease
By IPP Bureau - September 29, 2025
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
